

## Press release

NeuroVive Pharmaceutical AB (publ)  
556595-6538



### Number of shares and votes in NeuroVive Pharmaceutical AB (publ)

*Lund, Sweden, July 31, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced an increase of the number of shares and votes in NeuroVive of 1,084,224. This is a result of the during July performed directed rights issue and the subscription options program (series 2016/2017:2).*

Today, the last trading day of the month, there are in total 50,566,197 shares and votes in NeuroVive.

**For further information, please contact:**

Erik Kinnman, CEO NeuroVive, Tel: +46 (0)46 275 62 21 or [ir@neurovive.com](mailto:ir@neurovive.com)

**NeuroVive Pharmaceutical AB (publ)**

Medicon Village, SE-223 81 Lund, Sweden

Tel: +46 (0)46 275 62 20 (switchboard)

[www.neurovive.com](http://www.neurovive.com)

**About NeuroVive**

NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®) and one project in clinical phase I (KL1333) for genetic mitochondrial diseases. The R&D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to cancer and metabolic diseases such as NASH. The company's strategy is to advance drugs for rare diseases through clinical development and into the market. The strategy for projects within larger indications outside the core focus area is out-licensing in the preclinical phase. NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).

*This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 a.m. CEST on 31 July 2017.*